Arris, Bayer deal

ARRS partner Bayer said it plans to initiate development of BAY 17-1998, a second generation tryptase inhibitor developed by ARRS, to treat asthma. Bayer's goal is to enter the clinic within 12 months. The decision triggered an undisclosed milestone payment to ARRS. ...